323 related articles for article (PubMed ID: 28543700)
1. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapies for Melanoma: A New Standard of Care?
Smalley KS; Eroglu Z; Sondak VK
Am J Clin Dermatol; 2016 Apr; 17(2):99-105. PubMed ID: 26860106
[TBL] [Abstract][Full Text] [Related]
3. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.
Frederick DT; Salas Fragomeni RA; Schalck A; Ferreiro-Neira I; Hoff T; Cooper ZA; Haq R; Panka DJ; Kwong LN; Davies MA; Cusack JC; Flaherty KT; Fisher DE; Mier JW; Wargo JA; Sullivan RJ
PLoS One; 2014; 9(7):e101286. PubMed ID: 24983357
[TBL] [Abstract][Full Text] [Related]
4. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Nsengimana J; Laye J; Filia A; O'Shea S; Muralidhar S; Poźniak J; Droop A; Chan M; Walker C; Parkinson L; Gascoyne J; Mell T; Polso M; Jewell R; Randerson-Moor J; Cook GP; Bishop DT; Newton-Bishop J
J Clin Invest; 2018 May; 128(5):2048-2063. PubMed ID: 29664013
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.
Enewold L; Sharon E; Harlan LC
Oncol Res Treat; 2017; 40(4):174-183. PubMed ID: 28376479
[TBL] [Abstract][Full Text] [Related]
6. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Amini-Adle M; Arnault JP; Aubin F; Beneton N; Bens G; Brunet-Possenti F; Célerier P; Charles J; Crumbach L; Dalac S; Darras S; De Quatrebarbes J; Dinulescu M; Dutriaux C; Gaudy C; Gérard E; Giacchero D; Granel-Brocard F; Grange F; Jouary T; Kramkimel N; Lebbé C; Le Corre Y; Legoupil D; Lesage C; Lesimple T; Lorphelin JM; Mansard S; Martin L; Mary-Prey S; Maubec E; Meyer N; Mignard C; Montaudie H; Mortier L; Nardin C; Neidhardt Berard EM; Pagès Laurent C; Peuvrel L; Quereux G; Robert C; Saiag P; Saint-Jean M; Samimi M; Sassolas B; Scalbert C; Skowron F; Steff M; Stoebner PE; Trablesi S; Visseaux L; Zehou O; Boespflug A;
Ann Dermatol Venereol; 2024 Mar; 151(1):103243. PubMed ID: 38325268
[No Abstract] [Full Text] [Related]
7. Targeting
Phadke MS; Smalley KSM
J Clin Oncol; 2023 May; 41(14):2661-2664. PubMed ID: 36947724
[No Abstract] [Full Text] [Related]
8. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Zhao J; Chen AX; Gartrell RD; Silverman AM; Aparicio L; Chu T; Bordbar D; Shan D; Samanamud J; Mahajan A; Filip I; Orenbuch R; Goetz M; Yamaguchi JT; Cloney M; Horbinski C; Lukas RV; Raizer J; Rae AI; Yuan J; Canoll P; Bruce JN; Saenger YM; Sims P; Iwamoto FM; Sonabend AM; Rabadan R
Nat Med; 2019 Mar; 25(3):462-469. PubMed ID: 30742119
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients.
Khammari A; Nguyen JM; Saint-Jean M; Knol AC; Pandolfino MC; Quereux G; Brocard A; Peuvrel L; Saiagh S; Bataille V; Limacher JM; Dreno B
Cancer Immunol Immunother; 2015 Jul; 64(7):805-15. PubMed ID: 25846669
[TBL] [Abstract][Full Text] [Related]
10. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.
Hernandez B; Adissu HA; Wei BR; Michael HT; Merlino G; Simpson RM
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385676
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapeutic strategies for melanoma.
Zhang S; Xie R; Zhong A; Chen J
Chin Med J (Engl); 2023 Dec; 136(24):2923-2930. PubMed ID: 37144745
[TBL] [Abstract][Full Text] [Related]
12. Highlights of novel melanoma therapies presented at the 8th International Congress of the Society for Melanoma Research (SMR) Tampa, FL, November 9-11, 2011.
Herlyn D
Cancer Immunol Immunother; 2012 Jun; 61(6):949-51. PubMed ID: 22392191
[No Abstract] [Full Text] [Related]
13. Understanding the biology of melanoma and therapeutic implications.
Sullivan RJ; Fisher DE
Hematol Oncol Clin North Am; 2014 Jun; 28(3):437-53. PubMed ID: 24880940
[TBL] [Abstract][Full Text] [Related]
14. Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.
Wang R; Chen Y; Xie Y; Ma X; Liu Y
Int Immunopharmacol; 2024 May; 132():111989. PubMed ID: 38583243
[TBL] [Abstract][Full Text] [Related]
15. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.
Wu S; Singh RK
Curr Mol Med; 2011 Oct; 11(7):553-63. PubMed ID: 21707515
[TBL] [Abstract][Full Text] [Related]
16. Pathways and therapeutic targets in melanoma.
Shtivelman E; Davies MQ; Hwu P; Yang J; Lotem M; Oren M; Flaherty KT; Fisher DE
Oncotarget; 2014 Apr; 5(7):1701-52. PubMed ID: 24743024
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of metastatic melanoma: current strategies and future directions.
Batus M; Waheed S; Ruby C; Petersen L; Bines SD; Kaufman HL
Am J Clin Dermatol; 2013 Jun; 14(3):179-94. PubMed ID: 23677693
[TBL] [Abstract][Full Text] [Related]
18. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract][Full Text] [Related]
19. [Targeted therapies and immunotherapies in melanoma: A temporal approach to achieve optimal responses].
Braissand N; Coste I
Med Sci (Paris); 2023 Nov; 39(11):889-892. PubMed ID: 38018935
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.
Sahu AD; S Lee J; Wang Z; Zhang G; Iglesias-Bartolome R; Tian T; Wei Z; Miao B; Nair NU; Ponomarova O; Friedman AA; Amzallag A; Moll T; Kasumova G; Greninger P; Egan RK; Damon LJ; Frederick DT; Jerby-Arnon L; Wagner A; Cheng K; Park SG; Robinson W; Gardner K; Boland G; Hannenhalli S; Herlyn M; Benes C; Flaherty K; Luo J; Gutkind JS; Ruppin E
Mol Syst Biol; 2019 Mar; 15(3):e8323. PubMed ID: 30858180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
